Therapix Biosciences Ltd. 


Company Description:

Therapix Biosciences Ltd. (NASDAQ:TRPX) (TASE:TRPX) is a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs. With this focus, Therapix has initiated two internal drug development programs based on repurposing a U.S. Food and Drug  Administration approved synthetic cannabinoid (dronabinol). These two developments include: Joint Pharma developing THX-TS01 targeted to the treatment of Tourette Syndrome, and BrainBright Pharma developing THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments.

Latest News & Stories on Therapix Biosciences Ltd. (NASDAQ:TRPX) (TASE:TRPX)
Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: